Navigation Links
AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies
Date:4/20/2009

-- Key Data are New Releases for the Company Building on Milestones with Recent FDA Meetings and Technology Discoveries --

DENVER, April 20 /PRNewswire-FirstCall/ -- DXL625 monoclonal antibodies appear to be superior to commercial-stage antibodies in their ability to attach and deplete NHL in late stage pre-clinical studies, according to research conducted at InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V, http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology. The potency was achieved with comparable safety even at levels one hundred times that required for therapeutic efficacy, according to several studies presented at the American Association of Cancer Research (AACR) 100th Annual Meeting this past weekend. DXL625 is designed to bind CD20, a protein receptor expressed on normal B cells and over-expressed on cancerous B cells.

InNexus has previously announced that the United States Food and Drug Administration had completed its comprehensive review of the development plans for DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL). InNexus' submission included detailed information on plans for a Phase I clinical program, preclinical pharmacology and toxicology data and its current manufacturing plans. The FDA noted at the time that the plans were suitable for the manufacture of Phase I product of DXL625 onsite at InNexus.

"The studies are an important validation of our core drug discovery platform and confirm our ability to significantly advance the state of the art in developing potentially superior biologics for major medical and commercial opportunities," said Jeff Morhet, Chairman and CEO at InNexus.

InNexus and institutional researchers author
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Fralex reaches 100th patient milestone in fibromyalgia study
2. WolfPAC(sm) Integrated Risk Management Announces 100th Sale
3. eRT Completes Milestone 100th Thorough QT Study
4. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
5. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
6. Sinovac Announces Postponement of Annual General Meeting
7. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
8. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
9. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
10. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
11. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 2013 On average, developing a new ... billion dollars. Despite this investment, less than 10% of ... is your clinical trial design optimally structured to balance ... , Dr. Frederic Sax, Global Head of the Center ... of data, information and technology in upfront clinical trial ...
(Date:5/16/2013)... , May 16, 2013 /PRNewswire/ ... market research report is available in ... Diagnostic Cardiac Biomarkers for Acute Coronary ... Forecasts http://www.reportlinker.com/p01182969/MediPoint-Diagnostic-Cardiac-Biomarkers-for-Acute-Coronary-Syndromes---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... for Acute Coronary Syndromes - APAC ...
(Date:5/16/2013)... May 16, 2013 DNA Genotek, a leading ... for Africa’, a sponsorship program in conjunction with the African ... to improve access and reduce the cost of DNA ... as the Human Heredity and Health in Africa (H3 Africa) ... , The aim of the AfSHG is to ...
(Date:5/16/2013)... A number of residents in an apartment complex ... from abcactionnews.com, it was no thanks to the infestation of ... recommended to the management and everyone else suffering from the ... the public to try samples of it to prove it ... 11, 2013 determined that the complex invaded by ...
Breaking Biology Technology:Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 5MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 6MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 7MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 8DNA Genotek Inc. Announces Spit for Africa Program 2DNA Genotek Inc. Announces Spit for Africa Program 3Bed Bugs Plague Tarpon Springs Apartment Complex, Non-Pesticide Bed Bug Spray Recommended to Management by My Cleaning Products to Help 2Bed Bugs Plague Tarpon Springs Apartment Complex, Non-Pesticide Bed Bug Spray Recommended to Management by My Cleaning Products to Help 3
... 2011 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... of 6,700,000 shares of its common stock at a price ... is expected to close on or around Wednesday, April 13, ... the sole book-running manager in this offering and Sangamo has ...
... RICHMOND, Calif., April 7, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... to sell 6,700,000 shares of its common stock pursuant to ... Barclays Capital Inc. is the sole book-running manager in this ... day option to purchase up to 1,005,000 additional shares. ...
... The Center for Business Intelligence (CBI) announced today that ... in support of the relief efforts in Japan following a ... the fund while the organization matched employee donations. ... employees have displayed to help a nation in a desperate ...
Cached Biology Technology:Sangamo Announces Pricing of Public Offering of Common Stock 2Sangamo Announces Pricing of Public Offering of Common Stock 3Sangamo Announces Public Offering of Common Stock 2Sangamo Announces Public Offering of Common Stock 3The Center for Business Intelligence Donates to the American Red Cross, Matching Employee Contributions for Disaster Relief in Japan 2
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... MD (May 18, 2013) The AGA Research Foundation ... into the relationship between the gut microbiota, one of ... and disease. , The AGA Research Awards Panel ... from Massachusetts General Hospital and Harvard Medical School, Boston, ... recipient. Dr. Chan will receive $25,000 of funding, commencing ...
(Date:5/17/2013)... celebrate the science and technology of the region ... the inaugural Atlanta Science Festival, March 22-29, 2014. ... corporations, K-12 schools and universities, the festival will ... and adults at venues across the city. Learn ... annual Atlanta Science Festival is a collaboration of ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2First Atlanta Science Festival set for 2014 2
... Brook University Medical Center in New York have confirmed that ... and not a descendant of healthy humans dwarfed by disease. ... female specimen, researchers determined the "hobbit" to be a distinct ... Details of the study appear in the December issue ...
... advance with overtones of Star Trek phasers and other sci-fi ... internal on-off "switch" that paralyzes animals when exposed to a ... the light is turned off. When exposed to ordinary light, ... in the Journal of the American Chemical Society ...
... using human saliva to tell whether those stiff joints, memory ... red flags for disease, scientists are describing how the protein ... could lead to a simple, noninvasive test for better diagnosing ... a report in ACS, Journal of Proteome Research , ...
Cached Biology News:'Hobbits' are a new human species -- according to the statistical analysis of fossils 2
... are macroporous polystyrene beads for hydrophobic interaction ... for adsorbing organics of molecular weight less ... are useful for the adsorption of nonpolar ... the removal of detergents such as Triton ...
MAb to Catenin beta, N-terminal (exon 2) Catenin, beta, N-terminal (exon 2)...
... Phosphatase 2 (LPP2) fractionated ... solution Solution in ... 0.08% sodium azide. unique ... human LPP2 protein. The ...
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915...
Biology Products: